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INTRODUCTION 
I would like firstly to thank the President, Professor 
Mariano Esteban Rodriguez, and members of the Royal 
National Academy of Pharmacy, Instituto de España, for 
offering me the great honour of foreign membership. I am 
of course very thankful to Professor Alfonso Dominguez-
Gil for presenting my candidacy to your Academy. It is 
also with immense pleasure that I thank my great friend of 
many years, Professor Francisco Javier Burguillo for 
nominating me.    
Historical accounts of the development of medicines 
often start with the Egyptian Ebers papyrus, the 
ABSTRACT:  Over a century ago Gregor Mendel 
investigated quantitatively how physical traits of plants 
were passed on from one generation to the next. Soon 
after, William Bateson and Archibald Garrod showed 
the relevance of Mendel’s findings to human disease. 
Pharmacists have throughout history marketed 
themselves as experts who could treat disease with 
specific medicines. Their claims were however poorly 
validated until Louis Pasteur and Robert Koch 
established the microbial aetiology of many diseases. 
Effective antimicrobial agents and immunotherapies 
soon became available for an expanding range of 
infections, and personalisation of treatment became 
possible through sensitivity testing. Later, a greater 
understanding of the molecular pathogenesis of non-
microbial diseases led to the development of effective 
drugs, such as antihypertensives and anticoagulants. As 
a result, current pharmacopoeias bear no resemblance to 
their predecessors cluttered with predominantly useless 
drugs. With the unravelling of the double helical 
structure of DNA and greater understanding of its 
implications for health and disease, pharmacopoeias are 
being rewritten again. The new drugs enable an 
unprecedented level of individualisation of therapy. To 
optimise the promise of these drugs, input from a new 
generation of well-informed clinical pharmacists is 
needed. In this presentation, we identify some of these 
developments, and where input from pharmacists is 
most likely to be required. Will clinical pharmacists 
deliver? 
RESUMEN: Hace más de un siglo Gregor Mendel 
investigó cuantitativamente cómo se transmitían los 
rasgos físicos de las plantas de una generación a la 
siguiente. Poco después, William Bateson y Archibald 
Garrod mostraron la relevancia de los hallazgos de 
Mendel en las enfermedades humanas. A lo largo de la 
historia, los farmacéuticos se han considerado como 
expertos que podían tratar la enfermedad con 
medicamentos específicos. Sin embargo, sus 
afirmaciones fueron mal validadas hasta que Louis 
Pasteur y Robert Koch establecieron la etiología 
microbiana de muchas enfermedades. Los agentes 
antimicrobianos eficaces y las inmunoterapias pronto 
estuvieron disponibles para un número de infecciones en 
expansión y la personalización del tratamiento se hizo 
posible a través de pruebas de sensibilidad. 
Posteriormente, una mayor comprensión de la 
patogénesis molecular de las enfermedades no 
microbianas condujo al desarrollo de fármacos eficaces, 
tales como antihipertensivos y anticoagulantes. Como 
resultado, las farmacopeas actuales no guardan ningún 
parecido con sus predecesoras llenas de drogas 
básicamente inútiles. Con la desintegración de la doble 
estructura helicoidal del ADN y una mayor comprensión 
de sus implicaciones para la salud y la enfermedad, las 
farmacopeas se están volviendo a escribir. Los nuevos 
fármacos permiten un nivel sin precedentes de 
individualización de la terapia. Para optimizar la 
promesa de estos fármacos, se necesita el aporte de una 
nueva generación de farmacéuticos clínicos bien 
informados. En esta presentación, identificamos algunos 
de estos desarrollos y el lugar en el que el papel de los 
farmacéuticos es más probable que sea necesario. 
¿Cumplirán los farmacéuticos clínicos? 
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application of the doctrine of signatures in Europe, or the 
pharmacopoeia of the Chinese Yellow Emperor. For this 
lecture, delivered in the grand city of Madrid at the kind 
invitation of the Spanish Royal Academy of 
Pharmaceutical Sciences, I would like to begin here. For it 
was the Jesuit Cardinal Juan de Lugo, a Madrilenian, 
trained at your famous University of Salamanca, only a 
few miles from here, who brought the first truly effective 
medicine, the first ‘miracle’ drug, to the attention of the 
old world while serving as the Director of the apothecary 
at the Santo Spirito Hospital in Rome. That medicine, the 
cinchona bark or quinine, has saved countless lives since 
those mid-seventeenth century days when Father 
Bartholmé Tafur, the Peruvian Jesuit brought a small stock 
from San Pablo for his Jesuit superior. As demand grew, a 
Spanish Royal Order was issued in 1751 for the 
establishment of a Royal monopoly for trading cinchona 
bark, with supplies located in the Royal Pharmacy here in 
Madrid.  
There would not be another miracle medicine until the 
late nineteenth century although the therapeutic value of 
opium had been discovered centuries earlier, both in the 
East and West, and morphine was isolated as a pure 
medicinal chemical by Friedrich Sertürner in 1804 (1).  
The age of modern synthetic medicines is perhaps best 
anchored to the late 19th century with heroin and aspirin, 
both derivatives of naturally-occurring molecules; 
morphine and salicin (the salicylic acid glucoside prodrug) 
respectively. However, compared to the next revolution, 
brought about by the Pasteur’s and Koch’s discovery and 
proof of the microbial basis of many of the most 
devastating diseases, those advances were modest in terms 
of lives saved though not necessarily of pain avoided.  
THE BIRTH OF MODERN PERSONALISED 
MEDICINE 
The medical and pharmaceutical professions have 
always claimed that their clinical practice was 
personalised; the doctors that their diagnoses were specific 
and the pharmacists that their medicines were specifics. 
The emptiness of those claims have resonated down the 
centuries. Pasteur and Koch, and later Paul Ehrlich and 
Emil von Behring, established the methodology for 
validating such claims using the microscope and specific 
stains, and Behring’s serum therapy against diphtheria was 
the first truly effective antibody therapy. Jenner had 
earlier, of course, developed the first vaccine which 
eventually eliminated smallpox worldwide on an empirical 
basis before the cause was identified.  
VARIABILITY IN HUMAN RESPONSE 
One of the great puzzles for the early non-charlatan 
physicians was the wide variability in their patients’ 
responses to medicines. With the benefit of hindsight, 
some of the reasons are obvious: (i) natural variability in 
the chemical composition of plants (e.g. the variable 
pungency of Spanish chilies even of the same variety, and 
variation in the quality of wine, give some clear clues), (ii) 
misdiagnosis (e.g. of fevers), (iii) adulteration, deliberate 
or through ignorance, and (iv) variable dosing.  
Paracelsus (2) knew of the importance of dosing, 
stating, ‘All substances are poisons ... The right dose 
differentiates a poison and a remedy.' Arthur Koestler, the 
colourful writer, once imprisoned in Seville during the 
tumultuous period of your National history, knew after he 
failed in a suicide attempt. ‘Trying to commit suicide is a 
gamble the outcome of which will be known to the 
gambler only if the attempt fails, but not if it succeeds,’ he 
said when he tried again years later. Sadly, the dose and 
drug combination he chose did work that time, both for 
him and his wife in their double suicides. 
If drug response is so variable, then it is obvious that 




Figure 1 From one-size-fits-all to personalized therapy. 
THE BIRTH OF PHARMACOGENETICS 
Pharmacogenetics can be defined as the study of the 
impact of genetic variation on response to biologically 
active substances (pharmacons). More generally, the term 
pharmacogenetics can be enlarged by substituting ‘genetic 
variation’ with ‘inheritance.’ This extension is important 
as we inherit not only our genes from our parents but also 
our microbiome and our cultures, including our diet and 
our preferences, all of which may affect the action of the 
drugs we take.  
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Folklore ascribes the birth of pharmacogenetics to 
Pythagoras (3), the 6th to 5th century BC Greek 
philosopher, mathematician, and mystic because he 
forbade the eating of broad beans which causes haemolysis 
in some susceptible subjects. This causal association which 
was subsequently linked to an inborn deficiency in 
glucose-6-phosphate dehydrogenase (G6PD) established 
him as the first pharmacogeneticist in the eyes of many.   
Over two millennia later, the perceptive Charles 
Darwin recognised that adaptation contributed to wide 
variability in people’s responses to toxins and that through 
natural selection different groups could develop different 
levels of resistance to toxins at the population level. 
However, Darwin found it difficult to provide a 
mechanism for inheritance. He theorized that when 
children are conceived, they inherit a blend of their 
parents’ traits. Black and white would yield in-between 
shades of grey. He was unable to explain why blending did 
not continue until there was no more white or black.  
The theory of numbers developed by Pythagoras and 
his followers would help resolve Darwin’s dilemma. The 
sciences of numbers, they said, could be divided into two 
broad classes: numbers to describe how many (discrete 
mathematics) and numbers to describe how much 
(continuous mathematics). Pythagoras used continuous 
mathematics to describe music, and thereby also laid the 
foundation of harmonics.  
It was with the use of discrete mathematics that Gregor 
Mendel generated the data for his Laws of Inheritance with 
his studies of the genetics of peas.  
The discovery of monogenic diseases 
Darwin was not aware of Mendel’s work. In fact, even 
Mendel’s contemporaries working on plant breeding did 
not immediately recognise the significance of Mendel’s 
work. However, one biologist, William Bateson, working 
in Cambridge, soon recognised the wider significance of 
Mendel’s discoveries.  
Archibald Garrod, an astute London clinician inferred 
that alkaptouria, a strange and rare condition characterised 
by the deep browning, and eventual blackening of urine, 
when exposed to air, was due to a metabolic abnormality 
that led to the accumulation of homogentisic acid (4). 
When he discussed this abnormality, which he established 
was an ‘inborn error of metabolism,’ with Bateson, the 
latter worked out that it was indeed a hereditary 
abnormality, and even more importantly that its 
inheritance followed Mendel’s Law of segregation. Much 
of the genetics terminology that we use today owe their 
origins to Bateson (5). Over 6000 single-gene disorders are 
known and many, once fatal, are now manageable with 
recombinant replacement enzymes.  
Although he was no pharmacogeneticist during his 
lifetime, with his development of the mathematical 
concepts that allowed Mendel’s to develop his theory, 
Pythagoras has earned his place as one. What is discrete 
and what is continuous is of course often just an illusion as 
mathematicians studying wave mechanics have shown us. 
Werner Heisenberg (6) showed us that there was much 
uncertainty in the observation of physical phenomena. We 
have come to realise that in pharmacogenetics, discrete 
units of inheritance can produce apparent Darwinian 
‘blending’ when many genes contribute to a trait of 
interest, such as a drug response. Such traits are described 
as polygenic. Sometimes matters become more 
complicated and the traits are also affected by 
environmental influences as Darwin first surmised. Such 
traits are referred to as complex polygenic and 
multifactorial. Skin colour is an example but so are many 
drug responses. All pharmacists are of course aware of the 
potential clinical impact of drug-drug and drug-diet 
interactions.  
Much of the early pharmacogenetics work focussed on 
adverse effects of drugs (7). These included excessive 
prolongation of the action of suxamethonium (8), and the 
haemolysis induced by antimalarial drugs, notably 
primaquine (9,10). The latter case brought us back to 
Pythagoras as the adverse effect was associated once again 
with G6PD dehydrogenase (11). Such adverse effects led 
Motulsky to observe: 
‘In discussions of drug idiosyncrasy, careful distinction 
should be made between toxic reactions caused by 
immunologic mechanisms (drug allergy) and abnormal 
reaction caused by exaggeration or diminution of the usual 
effect of a given dose. Although some progress has been 
made in the study of mechanisms of drug allergy, little was 
known until recently about the pathogenesis of 
hypersusceptibility reactions and hyposusceptibility 
reactions. Data are available now which suggest that 
reactions of this type may be caused by otherwise 
innocuous genetic traits or enzyme deficiencies’ (12).  
The genetic basis of several hypersensitivity reactions, 
previously referred to as idiosyncratic, is now well 
established (13,14).  
PHARMACOKINETICS AND PHARMACODY-
NAMICS 
The discovery of the importance of the cytochrome 
P450 enzymes in the biotransformation of drugs, led to an 
explosion of studies on the impact of variants of those 
enzymes on drug action. Those studies coincided with the 
development of analytical and mathematical methods for 
probing the disposition of drugs in the body; a field 
defined by the terms pharmacokinetics and bioavailability. 
Many members of the cytochrome P450 enzyme 
superfamily have been identified. Although there was 
much hope that identification of dysfunctional variants 
would help us to personalise therapy, in practice the value 
of such insights has been limited for many reasons, 
including the following four. 
Firstly, our body, like the great city of Madrid or 
Barcelona, is complex; much more complex. There are 
many roads leading to and out of it. When one road is 
blocked, there is usually another road that one can use. So, 
when one metabolic pathway is blocked, the body uses 
another pathway to get rid of the drugs it receives. 
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Predicting the impact of an ineffective enzyme on a drug’s 
action is difficult for a body that has evolved over millions 
of years. Secondly, the relationships between dose and 
blood level, and blood level and activity are complex. It is 
usually better to measure blood level than to predict it 
from the genetic variants, particularly for drugs with 
narrow therapeutic windows. That is why for drugs such as 
vancomycin and tacrolimus, therapeutic blood level 
monitoring is still the best optimizer. Thirdly, when a 
pharmacodynamic effect or biomarker of beneficial or 
adverse effect is measurable it is usually better to use it 
than to go one step back to a defective genetic variant. 
That is why with warfarin, measuring blood clotting (INR; 
International Normalised Ratio) is better than using 
genetic algorithms. Well over one hundred studies have 
shown this. In any case, new drugs that are easier to use 
than warfarin are available. One day costs will come down 
to make them more affordable and perhaps make warfarin 
obsolete.  
Fourth, the road from drug to action is long and 
winding. For example, over one hundred genes are said to 
be involved in the action and disposition of warfarin.  
 
Figure 2. Processing and function of microRNAs. 
EPIGENETICS AND AN EXPANDING RNA 
WORLD 
The study of epigenesis, or the study of the functional 
impact of DNA modifications that do not involve any 
change in DNA sequence, initially applied to the study of 
embryonic development, now provides considerable 
insight into the action of drugs, including drug resistance.  
We know now that the bases that make up DNA are often 
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modified to provide control for gene expression.  
One of the greatest discoveries of recent years is that 
RNA molecules are not simply intermediates for 
translation to protein but that in their many different 
guises, they have many different functions in gene 
expression (15). MicroRNAs have attracted significant 
attention, and understanding their in-vivo processing 
(Figure 2) is leading to the development of new classes of 
medicines such as the oligos described below.  
OUR IMMUNE SELF AND IMMUNOTHERAPY 
Quite aside from the ageing process that makes us 
different with every passing day, we are also continuously 
shaped by our environment. To survive our body needs 
specialist cells that act as expert agents to recognise friend 
from foe, and for this we have evolved an exquisitely 
effective immunological surveillance system over 
evolutionary time: An immediate response innate system 
that recognises enemies met over evolutionary time, and 
an adaptive system that remoulds itself quickly to 
recognise new enemies both from within (e.g. in the form 
of cancer cells), and from outside, in the form of new 
microorganisms and new aggressive variants of old 
organisms (e.g. Zika and Ebola viruses, and new strains of 
influenza viruses). Cancer can be regarded as a failure of 
the immune system. Our resident microorganisms (our 
microbiome; Figure 3) participate more closely in our 
immunological remoulding than we thought even as 
recently as two decades ago (16,17).  
 
Figure 3. Tree of life. 
From the new insights into our immunological system, 
Behring’s first serum therapy, or antibody therapy, against 
diphtheria has now expanded into a whole host of 
immunotherapies, not only against microorganisms but 
also against cells that have become renegade as cancer 
cells , and self-molecules that are misrecognised by our 
immune system as foreign, and molecules that cause 
atherosclerosis.  
The nature of targeting 
Drug targeting or drug delivery has been on the minds 
of drug developers ever since Ehrlich proposed his magic 
bullet theory of drug action (18). His approach was 
structural modification of a lead compound to optimise the 
benefit-harm balance. Salvarsan his first magic bullet was 
compound 606 in the series he screened. This approach to 
drug screening is still current and has found new life in the 
repurposing of existing drugs. The second major approach 
to optimising drug delivery was through the development 
of sophisticated dosage forms such as osmotic pumps, 
transdermal patches. Depot injections, and liposomal 
systems. Both approaches contributed albeit modestly to 
the march of medicine towards better therapies.  
With the unravelling of the double-helical structure of 
DNA and detailed understanding of the expression of 
genes to functional proteins, drug developers began to 
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dream of targeting DNA itself, first crudely and non-
selectively with drugs that intercalated with or broke down 
DNA, but later more selectively at specific nucleotide 
sequences with short chains of nucleotides 
(oligonucleotides or oligos) (19,20). The road for oligos 
from the laboratory to the bedside has been a long and 
hard one but recent successes in the form of both licensed 
medicines (see below) and promising clinical reports 
suggest that the future may indeed been bright.  
New therapies 
From the greater insight into the phenomena which we 
have mentioned have emerged a whole host of new 
therapies that even Pasteur and Koch would have 
wondered at.  
(i) Small molecule targeted agents such as 
imatinib and gefitinib which have 
revolutionised the therapy of some cancers 
21).  
(ii) Macromolecular agents such as tacrolimus 
which make possible long-term engraftment 
of organs sometimes using age-old 
approaches (22).  
(iii) Exquisitely specific antibodies that tame 
severe arthritis and skin diseases as well as 
various cancers. 
(iv) Epigenetic medicines that treat hitherto 
intractable disease and reverse drug 
resistance (23).  
(v) Medicines such as ivacaftor that chaperone 
defective receptor molecules to improve their 
function (24).  
(vi) Medicines such as bortezomib, a proteasome 
inhibitor that acts on protein processing and 
cell-death (25).  
(vii) Antiviral agents that can cure rather than 
only suppress (26).  
(viii) Gene therapies that have less severe off-
target effects and prolong life meaningfully 
(27,28).  
(ix) Licensed antisense oligonucleotides such as 
eteplirsen and nusinersen that improve the 
production of functional proteins in severe 
muscular dystrophies (29,30).  
FUTURE THERAPIES 
Small molecules will no doubt continue to be important 
but will most likely be increasingly targeted.  As such they 
may require companion diagnostics to optimise their use.  
Several such drugs are already on the market. 
Individualisation of therapy will require more pre-
prescription testing but great care much be exercised so 
that unnecessary tests are not introduced (31,32).  
We can perhaps also predict that macromolecular and 
cellular therapies will increase in importance in the form 
of a widening range of immunotherapies not only for 
treatment of disease but also for its prophylaxis.  
The discovery of how to reprogram somatic cells to 
pluripotency led to hopes that regenerative medicine could 
at last become reality (33). It was hoped that with the use 
of a patient’s own cells (autologous), problems associated 
with immune rejection and poor engraftment could be 
overcome. However, clinical success has remained elusive 
(34) and the use of donor (allogenic) cells for induction 
might well be the better way forward. The history of the 
development of therapeutic monoclonal antibodies show 
us that persistence eventually pays off. Sales of such 
antibodies not exceed over 50 billion dollars annually (35). 
A recent report of regeneration of vision with surgical 
interventions that preserve endogenous stem or progenitor 
cells provides cause for optimism (36,37). 
ROLE OF THE CLINICAL PHARMACIST 
What then is the role of the clinical pharmacist in this 
new genomic era? Over four decades ago, the American 
Association of Colleges of Pharmacy, recognising the 
rapid changes taking place in pharmacy practice 
commissioned and published an influential report on the 
future of pharmacy. It recognised that despite ‘the real and 
multifaceted differentiation in the practice roles of 
pharmacists, there is a common body of knowledge skill, 
attitudes and behaviour which all pharmacists must 
possess’ (38). In redefining pharmacy, they called 
attention to three key elements: firstly, ready and 
comprehensive knowledge of drugs, their actions and use; 
secondly, competencies to serve; and thirdly service to 
meet both individual and societal needs.’ 
 I think that, by and large, these elements are still key. 
For this presentation, I draw attention to another of their 
main perceptions: ‘a lack of an adequate number of 
clinical scientists who can relate their specialized 
scientific knowledge to the development of the practice 
skills required to provide effective, efficient and needed 
patient services.’ Although as we have indicated, what is a 
drug has expanded to include an array of immunotherapies 
and cellular therapies, the main challenge for schools and 
leaders of pharmacy is probably still the training of 
sufficient numbers of clinical scientists with expert 
knowledge of drugs. 
It may be fitting to end my presentation with Paul 
Ehrlich’s words, uttered over a century ago: 
‘..to allude to my quotation from Bacon, we no longer 
find ourselves lost on a boundless sea but we have already 
caught a distinct glimpse of the land which we hope, nay, 
which we expect, will yield rich treasures for biology and 
therapeutics’ (39).  
Many rich treasures have indeed been fdiscovered. 
Many more will follow. However, the licensing of targeted 
agents now involves testing fewer subjects prior to 
marketing. As custodians of drugs, clinical pharmacists 
will no doubt wish to ponder on some more of Ehrlich’s 
words: 
‘I have before me the records of over 9,000 cases. … 
The primary object of these large numbers is to explore the 
possible dangers of the remedy, because nothing less than 
an accurate knowledge of these will provide a sound basis 
for the introduction of a new medicament into general 
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medical use. Indeed, it has often been demanded that in the 
treatment of man …. only such agents shall be used as are 
absolutely free from danger. Were one to yield to this 
demand, any progress of therapeutics, in a 
chemotherapeutic sense, would be altogether impossible; 
for substances which are capable of freeing the living body 
from an infection cannot be regarded as indifferent; there 
must rather be inherent in them a certain characteristic 
toxicity’ (40).  
The use of medicines always involves important trade-
offs and clinical pharmacists may help their patients in 
better appreciating this.  
Acknowledgments: The Figures are all taken from the 
author’s Genomic Medicine 101 (41).  
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